Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results67% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (6)
Early P 1 (1)
P 1 (3)
P 2 (7)
P 3 (1)

Trial Status

Recruiting9
Active Not Recruiting4
Completed4
Terminated2
Suspended1
Unknown1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT06285825Phase 2RecruitingPrimary

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

NCT06802146Early Phase 1Recruiting

Early Intervention in High Risk CCUS

NCT07025512Phase 2Suspended

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

NCT07081087RecruitingPrimary

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

NCT02958462Not ApplicableRecruiting

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

NCT04419649Phase 2Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

NCT06430788Phase 2Recruiting

A Study of Emapalumab for Pediatric Aplastic Anemia

NCT05236764Not ApplicableActive Not Recruiting

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

NCT06773871Not ApplicableRecruiting

Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions

NCT04873102Phase 2Recruiting

Danazol for Treatment of Cytopenias in Patients With Cirrhosis

NCT04741945Phase 2Recruiting

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

NCT03682029Not ApplicableActive Not Recruiting

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

NCT06276036Not ApplicableActive Not RecruitingPrimary

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

NCT02065869Phase 1Terminated

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

NCT03733249Phase 1Terminated

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

NCT03301168Phase 1Active Not Recruiting

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

NCT01928537Phase 3Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT04070612CompletedPrimary

National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.

NCT03026751UnknownPrimary

Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing

NCT02104440Phase 2CompletedPrimary

Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro

Scroll to load more

Research Network

Activity Timeline